tradingkey.logo

Oric Pharmaceuticals Inc <ORIC.OQ> expected to post a loss of 51 cents a share - Earnings Preview

ReutersMay 2, 2025 11:37 AM
  • Oric Pharmaceuticals Inc ORIC.OQ ORIC.O is expected to show no change in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Oric Pharmaceuticals Inc is for a loss of 51 cents per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 0.7% in the last three months. ​

  • Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $17.00​, above​ its last closing price of $5.57. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.52

-0.51

-0.51

Met

-0.9

Sep. 30 2024

-0.48

-0.48

-0.49

Missed

-2.4

Jun. 30 2024

-0.41

-0.41

-0.45

Missed

-9.2​

Mar. 31 2024

-0.45

-0.44

-0.37

Beat

15.2

​​Dec. 31 2023

-0.49

-0.49

-0.49

Met

-0.7

Sep. 30 2023

-0.46

-0.46

-0.44

Beat

4.7​

Jun. 30 2023

-0.57

-0.57

-0.50

Beat

12.1

Mar. 31 2023

-0.54

-0.54

-0.53

Beat

1.9

This summary was machine generated May 2 at 11:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI